AlisQI is a Quality Management platform built for process and batch manufacturers who want operational control without adding administrative overhead.
Where many QMS platforms were designed around document storage and event tracking, AlisQI was architected as a data-first system. Quality, laboratory, and production data are structured and connected in a single operational backbone. This enables teams to see deviations earlier, understand performance trends in context, and act before issues escalate into waste, rework, or customer complaints.
The platform includes modular capabilities across document control, training, deviations, CAPA, audits, risk management, supplier quality, SPC, and EHS. These capabilities are deployed through focused, ready-to-use Solvers that combine workflows, logic, dashboards, and analytics to address specific operational challenges without unnecessary scope.
Because the system is built on structured, connected data, manufacturers can apply practical AI directly inside their workflows. This includes automated extraction of supplier COA data without predefined templates, conversational access to quality records, intelligent rule generation, and pattern recognition across incidents to strengthen corrective action effectiveness.
Solvers are production-ready from the outset and evolve as products, processes, or sites change. Improvements do not require custom development or large IT programs, allowing organizations to modernize quality step by step.
Manufacturers across chemicals, plastics, packaging, food and beverage, automotive, and industrial sectors use AlisQI to reduce firefighting, increase predictability, strengthen compliance, and turn quality data into operational intelligence.
Learn more
Teradata VantageCloud: The Complete Cloud Analytics and AI Platform
VantageCloud is Teradata’s all-in-one cloud analytics and data platform built to help businesses harness the full power of their data. With a scalable design, it unifies data from multiple sources, simplifies complex analytics, and makes deploying AI models straightforward.
VantageCloud supports multi-cloud and hybrid environments, giving organizations the freedom to manage data across AWS, Azure, Google Cloud, or on-premises — without vendor lock-in. Its open architecture integrates seamlessly with modern data tools, ensuring compatibility and flexibility as business needs evolve.
By delivering trusted AI, harmonized data, and enterprise-grade performance, VantageCloud helps companies uncover new insights, reduce complexity, and drive innovation at scale.
Learn more
Genedata Biologics
Genedata Biologics® significantly advances the creation of biotherapeutics such as bispecifics, ADCs, TCRs, CAR-Ts, and AAVs, offering an all-encompassing solution for the sector. Esteemed as a premier platform in its domain, it seamlessly integrates all discovery processes, empowering researchers to focus on true innovation. By employing a cutting-edge system specifically designed to digitize the biotherapeutic discovery journey, research timelines can be notably expedited. This platform streamlines complex R&D activities by aiding in the design, tracking, testing, and evaluation of new biotherapeutic entities. It accommodates a variety of formats, including antibodies, bi- or multi-specifics, ADCs, novel scaffolds, and therapeutic proteins, along with engineered therapeutic cell lines like TCRs and CAR-T cells. As a fully integrated data backbone, Genedata Biologics links all R&D activities, from library design and immunization to selection and panning, molecular biology, screening, protein engineering, expression, purification, and analytics, resulting in thorough evaluations of candidate developability and manufacturability. This comprehensive integration not only enables researchers to make well-informed choices but also fosters a culture of exploration and advancement in biotherapeutic innovation. Ultimately, the synergy of these capabilities positions Genedata Biologics as a vital asset in the competitive landscape of biopharmaceutical development.
Learn more
Aurora Drug Discovery
Aurora applies concepts from quantum mechanics and thermodynamics alongside an advanced continuous water model to evaluate solvation effects when determining the binding affinities of ligands. This approach is notably different from the conventional scoring functions that are commonly used to predict binding affinities. By incorporating both entropy and aqueous electrostatic elements into their calculations, the algorithms developed by Aurora provide notably more accurate and dependable estimates of binding free energies. The binding free energy, a key thermodynamic measure, fundamentally dictates the interaction between a ligand and a protein and is directly associated with the experimentally measurable inhibition constant (IC50). Various elements, such as electrostatic interactions, quantum phenomena, solvation dynamics, and the statistical behavior of molecules, all play a role in influencing this free energy (F). The non-additive characteristics of F arise primarily from two key components: the synergistic effects of electrostatic and solvation energies, as well as the entropy present in the system. Gaining a comprehensive understanding of these factors enhances the insight into the molecular interactions that are crucial for effective drug design and development.
Learn more
